GE Healthcare Technologies Inc. - Q2 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. GE Healthcare Technologies Inc. is a global provider of medical technology, pharmaceutical diagnostics, and AI/cloud solutions. In Q2 2026, the Company reorganized its reporting structure, combining the Imaging and Advanced Visualization Solutions (AVS) businesses into a new segment, Advanced Imaging Solutions (AIS). The Company now reports three segments: AIS, Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS).
Key Financial Metrics
| Metric (in millions) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Total Revenues | $5,295 | $5,007 | $10,425 | $9,784 |
| Operating Income | $739 | $654 | $1,254 | $1,283 |
| Net Income (Attributable to GEHC) | $561 | $486 | $950 | $1,049 |
| Diluted EPS | $1.24 | $1.06 | $2.08 | $2.29 |
| Operating Cash Flow (YTD) | $458 | $344 | $458 | $344 |
| Free Cash Flow (YTD) | $180 | $106 | $180 | $106 |
| Total Debt | $10,093 | $10,003 | $10,093 | $10,003 |
| Cash & Equivalents | $2,105 | $4,512 | $2,105 | $4,512 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 5.7% in Q2 and 6.6% YTD, driven by strong growth in PDx (15.6% Q2) and AIS (7.9% Q2). This was partially offset by a 13.3% decline in PCS revenues due to operational and fulfillment challenges.
- Profitability: Operating income rose 13.1% in Q2 to $739 million, aided by a $106 million pre-tax benefit from tariff refunds. However, YTD operating income decreased 2.3% due to cost inflation and higher operating expenses.
- Acquisitions: The Company acquired Intelerad for approximately $2.3 billion in cash in March 2026, significantly impacting investing cash flows and adding to the AIS segment. The acquisition of Nihon Medi-Physics (NMP) in 2025 continues to drive PDx growth.
- Tariff Impact: While tariffs negatively impacted operating income by $68 million in Q2, the Company recognized $106 million in tariff refunds related to 2025 costs, resulting in a net positive impact on the quarter's bottom line.
- Share Repurchases: The Company repurchased 3.3 million shares for $200 million in Q2 and 4.7 million shares for $300 million YTD. $500 million remains available under the repurchase program.
Guidance, Outlook, and Risks
- Outlook: Management expects continued material impacts from global tariffs and trade restrictions. While mitigation actions are underway, they may not fully offset costs. The Company anticipates continued growth in PDx and AIS, while PCS faces ongoing headwinds.
- Tariff Refunds: The Company is actively pursuing refunds for tariffs imposed under the International Emergency Economic Powers Act (IEEPA). While $107 million has been received and $38 million recorded as a receivable, the ultimate timing and amount of future recoveries remain uncertain.
- Geopolitical Risks: Conflicts in the Middle East, Russia, and Ukraine continue to impact supply chains, logistics costs, and service levels. The Company monitors potential disruptions in the China market due to local competition and procurement policies.
- Legal Proceedings: A significant legal matter involving the Iraqi Ministry of Health contracts remains in the discovery process following a Court of Appeals decision in January 2026. The Company cannot currently estimate a meaningful loss range.
- Restructuring: The Company expects to incur an additional $38 million in restructuring expenses over the next 12 months, primarily for employee termination benefits and asset write-downs.
Investor Verification Checklist
- Tariff Refund Realization: Verify the actual cash receipt and timing of the remaining $38 million receivable and future IEEPA refund claims.
- PCS Segment Turnaround: Monitor the root causes and resolution timeline for the operational and fulfillment challenges driving the 13.3% revenue decline in the Patient Care Solutions segment.
- Intelerad Integration: Assess the integration progress and synergy realization of the $2.3 billion Intelerad acquisition within the AIS segment.
- Debt Servicing: Review the impact of the new $650 million Delayed Draw Term Loan on future interest expenses and leverage ratios.
- Legal Exposure: Track developments in the Iraqi Ministry of Health litigation and the potential for material indemnification obligations related to the IRS audit of the GE consolidated tax returns.